Subdermal Contraceptive Implants Market Players:
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Shanghai Dahua Pharmaceutical Co., Ltd,
- Bayer AG
- Wyeth Pharmaceuticals
- Baxter
- Gerresheimer AG
- Theramex
- Contraline, Inc.
- Pfizer, Inc.
- Novartis AG
- Schott AG
- Eli Lilly and Company
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of subdermal contraceptive implants is assessed at USD 1.15 billion.
The global subdermal contraceptive implants market size was valued at around USD 1.11 billion in 2025 and is projected to grow at a CAGR of more than 3.7%, reaching USD 1.6 billion revenue by 2035.
North America is predicted to hold the largest share of 55% by 2035, impelled by the widespread availability of contraceptive implants such as Nexplanon.
Key players in the market include Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, Gerresheimer AG, Pfizer, Inc., Novartis AG, Schott AG, Eli Lilly and Company.
